Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer ...
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth ...
Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
Zoe Lazarre, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value ...
Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new ...
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results